A new anti-obesity drug treatment: First clinical evidence that, antagonising glutamate-gated Ca2+ ion channels with memantine normalises binge-eating disorders

We suggest to treat human obesity by protecting the hypothalamic signalling cascade of leptin action with low to moderate affinity, non-competitive NMDA-R antagonists that selectively block the GLU-gated Ca2+ ion channels.